Tag: primary myelofibrosis market analysis

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

#Primary Myelofibrosis Market Growth Potential: How Will Market Size Shift Through 2030?#_x000D_

The primary myelofibrosis market has experienced significant expansion recently. This market is projected to grow from $0.84 billion in 2025 to $0.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. The historical growth of this market can be attributed to several factors including limited therapeutic options, challenges with delayed and incorrect diagnosis, low disease awareness, a reliance on conventional treatments, and a relatively small patient population._x000D_

_x000D_

The primary myelofibrosis market is anticipated to observe significant expansion over the next few years. It is projected to attain a value of $1.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This projected growth throughout the forecast period stems from the advancement of novel targeted therapies, heightened clinical trial activities, breakthroughs in genetic and molecular diagnostics, increased investment in hematology research, and the growing implementation of personalized medicine. Prominent trends for the forecast period include enhanced awareness and earlier diagnosis of primary myelofibrosis, an increase in targeted therapies and customized treatment methods, broader adoption of advanced diagnostic tools, the expansion of clinical trials and research initiatives, and a concentrated effort on patient support programs and disease management._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=87302757&type=smp&name=Primary%20Myelofibrosis%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Primary Myelofibrosis Market Opportunity Drivers: What’s Unlocking New Revenue Potential?#_x000D_

The future growth of the primary myelofibrosis market is anticipated to be significantly propelled by the rising occurrence of myelofibrosis. Myelofibrosis is defined as a rare type of bone marrow cancer that disrupts the body’s normal blood cell production, leading to extensive scarring within the bone marrow and consequently causing severe anemia, weakness, fatigue, and an enlarged spleen. This increasing prevalence of myelofibrosis is primarily attributed to the aging population, as the condition most frequently affects individuals over the age of 60, with longer life expectancies contributing to a higher number of diagnosed cases. The expanding prevalence of myelofibrosis also enhances the management of primary myelofibrosis by stimulating research, improving early diagnosis, expanding treatment options, and advocating for superior clinical guidelines and specialized care. As an illustration, a report published in November 2024 by the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, stated that myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. Thus, the escalating prevalence of myelofibrosis is a key factor driving the expansion of the primary myelofibrosis market._x000D_

_x000D_

#Primary Myelofibrosis Market Segment Analysis And Revenue Potential#_x000D_

The primary myelofibrosis market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types_x000D_

2) By Services: Treatment, Diagnosis_x000D_

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms_x000D_

4) By Age: Adult, Child, Geriatric_x000D_

5) By End User: Hospitals, Clinics, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations_x000D_

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis_x000D_

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders_x000D_

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis_x000D_

_x000D_

#Primary Myelofibrosis Market Innovation Trends Shaping Future Development#_x000D_

Leading companies in the primary myelofibrosis market are dedicated to developing innovative products, such as Janus kinase 2 inhibiting tablets, to enhance symptom management and slow the progression of the disease. Janus kinase 2 (JAK2) inhibiting tablets are oral medications that block the activity of the JAK2 enzyme, which is involved in the irregular signaling pathways causing excessive blood cell production in primary myelofibrosis. These tablets are instrumental in reducing spleen size, alleviating fatigue and bone pain, and hindering disease progression. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, introduced Omjjara (momelotinib) as a new treatment for myelofibrosis. Approved by South Korea’s Ministry of Food and Drug Safety, it is designed for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms such as anemia, an enlarged spleen, and fatigue. Its approval is substantiated by clinical trial data demonstrating significant improvements in anemia, spleen size, and overall symptoms when compared to existing treatments._x000D_

_x000D_

#Primary Myelofibrosis Market Key Players Shaping Industry Direction#_x000D_

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd. _x000D_

_x000D_

#View The Full Primary Myelofibrosis Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Primary Myelofibrosis Market Geographic Analysis: Where Is Demand Accelerating Fastest?#_x000D_

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Primary Myelofibrosis Market Expansion From $0.89 Billion In 2026 To $1.14 Billion In 2030

The market for primary myelofibrosis has experienced robust expansion over recent years. Its value is projected to rise from $0.84 billion in 2025 to $0.9 billion in 2026, reflecting a compound annual growth rate of 6.4%. This historical growth was driven by factors such as scarce treatment alternatives, frequent delays in diagnosis and instances of misdiagnosis, insufficient public awareness of the condition, a dependence on traditional therapies, and a relatively limited patient population.

The market for primary myelofibrosis is anticipated to experience robust expansion over the coming years. By 2030, its value is projected to reach $1.14 billion, reflecting a compound annual growth rate (CAGR) of 6.2%. This forecasted growth is driven by factors such as the creation of innovative targeted therapies, a rise in clinical trial initiatives, progress in genetic and molecular diagnostics, increased funding for hematology research, and a greater emphasis on personalized medicine. Key developments expected in this period include heightened awareness and earlier detection of the condition, an expansion of targeted and individualized treatment strategies, broader implementation of sophisticated diagnostic technologies, a surge in clinical trial and research efforts, and a stronger focus on patient support programs and comprehensive disease management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Primary Myelofibrosis Market Growth Factors Supporting Long-Term Expansion

A rise in the prevalence of myelofibrosis is anticipated to stimulate expansion in the primary myelofibrosis market moving forward. This condition, a rare bone marrow cancer, interferes with the body’s regular production of blood cells, causing significant scar tissue formation in the marrow that leads to serious anemia, weakness, fatigue, and a swollen spleen. The growing frequency of myelofibrosis is largely attributed to an aging demographic, as it commonly affects individuals beyond the age of 60, and extended lifespans are increasing the number of confirmed cases. Higher prevalence rates are enhancing the management of primary myelofibrosis by fueling research efforts, improving early detection, broadening available therapies, and fostering better clinical standards and specialized care approaches. For example, in November 2024, a report from the National Institute for Health and Care Excellence, a UK-based independent public body, indicated that myelofibrosis occurs in 3.2 per 100,000 people in the UK, with an incidence rate of 0.6 per 100,000. Consequently, the increasing occurrence of myelofibrosis is propelling growth in the primary myelofibrosis market.

Primary Myelofibrosis Market Categorization By Product Type And Application

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Primary Myelofibrosis Market Industry Trends Shaping Future Revenue Growth

Key players in the primary myelofibrosis market are concentrating their efforts on developing advanced treatments, such as Janus kinase 2 inhibiting tablets, with the goal of enhancing symptom management and decelerating disease advancement. These oral medications work by suppressing the activity of the JAK2 enzyme, which plays a central role in the irregular signaling pathways that drive excessive blood cell production in primary myelofibrosis. The tablets contribute to reducing spleen size, easing symptoms like fatigue and bone pain, and slowing the overall progression of the disease. As an example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology firm based in Korea, introduced Omjjara (momelotinib), a novel therapeutic option for myelofibrosis. This drug has received approval from South Korea’s Ministry of Food and Drug Safety and is designed for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who are also dealing with moderate to severe anemia. Omjjara functions as an oral inhibitor of Janus kinases (JAK1 and JAK2) as well as activin A receptor type 1 (ACVR1), targeting symptoms like anemia, an enlarged spleen, and fatigue. Its authorization is backed by clinical trial results that show considerable enhancements in anemia, spleen size, and overall symptom relief when compared to existing therapies.

Primary Myelofibrosis Market Company Landscape And Strategic Competition

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Access The Complete Primary Myelofibrosis Market Report:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Primary Myelofibrosis Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Primary Myelofibrosis Market Over The Forecast Period?

The primary myelofibrosis market has experienced significant growth in recent years. It is projected to increase from $0.84 billion in 2025 to $0.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. Historically, this expansion has been influenced by factors such as limited therapeutic options, delayed diagnosis and misdiagnosis, low disease awareness, reliance on conventional treatments, and a small patient population.

The primary myelofibrosis market size is poised for robust expansion in the upcoming years. It is forecast to grow to $1.14 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This anticipated growth throughout the forecast period stems from the advancement of novel targeted therapies, a rise in clinical trial engagements, improvements in genetic and molecular diagnostics, increasing investment in hematology research, and the growing acceptance of personalized medicine. Prominent trends for the forecast period encompass heightened awareness and prompt diagnosis of primary myelofibrosis, an escalation in targeted therapies and individualized treatment approaches, greater integration of advanced diagnostic tools, an expansion of clinical trials and research endeavors, and a dedicated focus on patient support programs and disease management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Market Drivers Are Helping Shape The Primary Myelofibrosis Market Expansion?

The primary myelofibrosis market is set to experience growth driven by the escalating prevalence of myelofibrosis. Myelofibrosis is a rare bone marrow cancer that interferes with normal blood cell production, causing significant scarring in the bone marrow and leading to severe anemia, weakness, fatigue, and an enlarged spleen. This rise in prevalence is largely attributable to the aging population, given that the condition predominantly impacts individuals over the age of 60, with longer life expectancies contributing to more diagnoses. The increased prevalence also positively influences the management of primary myelofibrosis by stimulating research, improving early detection, expanding treatment choices, and fostering superior clinical guidelines and specialized care. For example, a November 2024 report by the National Institute for Health and Care Excellence highlighted a myelofibrosis prevalence of 3.2 per 100,000 people and an incidence rate of 0.6 per 100,000 in the UK. Consequently, the growing prevalence of myelofibrosis is a key driver for the primary myelofibrosis market.

How Is Segment Classification Applied In The Primary Myelofibrosis Market?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

What Trends Are Affecting The Growth Of The Primary Myelofibrosis Market?

Leading companies active in the primary myelofibrosis market are concentrating on developing advanced products, such as Janus kinase 2 inhibiting tablets, to enhance symptom management and slow down disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral drugs that impede the function of the JAK2 enzyme, which is implicated in the irregular signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets contribute to reducing spleen size, alleviating symptoms of fatigue and bone pain, and decelerating the disease’s advancement. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology company based in Korea, introduced Omjjara (momelotinib), a new treatment for myelofibrosis. This treatment is approved by South Korea’s Ministry of Food and Drug Safety and is intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms such as anemia, an enlarged spleen, and fatigue. Its approval is supported by clinical trial data demonstrating significant improvements in anemia, spleen size, and overall symptoms when compared to existing treatments.

Which Companies Form The Competitive Landscape Of The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Access The Complete Primary Myelofibrosis Market Report:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Region Has The Strongest Presence In The Primary Myelofibrosis Market?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Primary Myelofibrosis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Primary Myelofibrosis Market Grow Between 2026 And 2030?

The market size for primary myelofibrosis has demonstrated substantial growth in recent years. It is projected to expand from $0.84 billion in 2025 to $0.9 billion in 2026, at a compound annual growth rate (CAGR) of 6.4%. The expansion observed historically can be attributed to several factors including limited available therapeutic options, instances of delayed diagnosis and misdiagnosis, insufficient disease awareness, a dependence on conventional treatments, and a restricted patient population.

The primary myelofibrosis market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $1.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This projected increase can be attributed to several factors, including the emergence of innovative targeted treatments, a rise in clinical trial engagement, progress in genetic and molecular diagnostic methods, increased funding for hematology research, and the expanding implementation of personalized medicine. Key developments anticipated during this timeframe involve heightened awareness and earlier detection of primary myelofibrosis, an expansion of targeted therapies and individualized treatment strategies, broader use of sophisticated diagnostic instruments, an increase in clinical studies and research endeavors, and a greater emphasis on patient support initiatives and disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

Which Strong Drivers Are Impacting The Primary Myelofibrosis Market Growth?

The growing incidence of myelofibrosis is poised to stimulate the expansion of the primary myelofibrosis market in the future. Myelofibrosis is defined as an uncommon form of bone marrow cancer which interferes with the body’s standard blood cell production, causing significant scarring within the bone marrow, and manifesting as severe anemia, weakness, tiredness, and an enlarged spleen. The heightened prevalence of myelofibrosis largely stems from an aging population, given that the ailment predominantly impacts those above 60 years old, with extended life expectancies contributing to an elevated count of identified instances. An escalating occurrence of myelofibrosis facilitates advancements in the management of primary myelofibrosis by stimulating research, refining early detection, broadening available treatments, and encouraging superior clinical protocols and specialized services. For example, in November 2024, the National Institute for Health and Care Excellence, an independent executive non-departmental public body situated in the UK, reported that myelofibrosis affects 3.2 per 100,000 people in the UK and has an incidence rate of 0.6 per 100,000. Consequently, the growing incidence of myelofibrosis is fueling the expansion of the primary myelofibrosis market.

What Are The Key Segment Divisions In The Primary Myelofibrosis Market Segment Structure?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Trends Are Guiding The Direction Of The Primary Myelofibrosis Market?

Leading companies within the primary myelofibrosis market are prioritizing the development of innovative products, such as Janus kinase 2 inhibiting tablets, to enhance symptom management and slow disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral medications that block the activity of the JAK2 enzyme, which plays a role in the abnormal signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets help reduce spleen size, alleviate symptoms like fatigue and bone pain, and decelerate the disease’s advancement. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, launched Omjjara (momelotinib), a new treatment for myelofibrosis. This medication is approved by South Korea’s Ministry of Food and Drug Safety and is intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), proving effective in addressing symptoms such as anemia, enlarged spleen, and fatigue. Its approval is backed by clinical trial data that demonstrated significant improvements in anemia, spleen size, and overall symptoms compared to existing treatments.

Which Organizations Are Engaged In The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Get The Full Primary Myelofibrosis Market Report:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Region Is The Leading Market For The Primary Myelofibrosis Market?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Primary Myelofibrosis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Primary Myelofibrosis Market At The End Of The 2026–2030 Forecast Period?

The primary myelofibrosis market size has seen significant expansion in recent years. It is anticipated to increase from $0.84 billion in 2025 to $0.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. The factors contributing to this growth in previous periods include a scarcity of treatment choices, challenges with timely and accurate diagnosis, insufficient public understanding of the condition, a dependence on traditional medical interventions, and a relatively small number of patients.

The primary myelofibrosis market size is anticipated to undergo substantial growth in the upcoming years. It is projected to reach $1.14 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.2%. This expansion during the forecast period is attributable to the development of novel targeted therapies, increasing clinical trial activities, advancements in genetic and molecular diagnostics, growing investment in hematology research, and the rising adoption of personalized medicine. Significant trends expected during this period include heightened awareness and early diagnosis of primary myelofibrosis, an expansion in targeted therapies and personalized treatment approaches, increased utilization of advanced diagnostic tools, growth in clinical trials and research activities, and a focus on patient support programs and disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Primary Myelofibrosis Market?

The expanding occurrence of myelofibrosis is projected to drive the growth of the primary myelofibrosis market moving forward. Myelofibrosis is defined as an uncommon form of bone marrow cancer that interferes with the body’s normal blood cell production, resulting in significant scarring within the bone marrow, which in turn causes severe anemia, weakness, fatigue, and an enlarged spleen. This increase in myelofibrosis prevalence is largely attributed to the global aging population, given that the condition predominantly impacts individuals over 60, with extended life expectancies leading to more diagnoses. The growing incidence of myelofibrosis contributes to better management of primary myelofibrosis through stimulating research, improving early detection, expanding treatment choices, and fostering enhanced clinical guidelines and specialized care. As an illustration, a report released in November 2024 by the National Institute for Health and Care Excellence, an independent executive non-departmental public body based in the UK, indicated that myelofibrosis affects 3.2 per 100,000 people in the UK, with an incidence rate of 0.6 per 100,000. Consequently, the rising prevalence of myelofibrosis is propelling the expansion of the primary myelofibrosis market.

What Segment Types Make Up The Primary Myelofibrosis Market?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Market Trends Are Creating New Opportunities In The Primary Myelofibrosis Market?

Leading companies within the primary myelofibrosis market are concentrating on developing innovative products, such as Janus kinase 2 inhibiting tablets, to enhance symptom control and slow disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral medications designed to block the activity of the JAK2 enzyme, which plays a role in the abnormal signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets contribute to reducing spleen size, alleviating symptoms of fatigue and bone pain, and impeding the disease’s advancement. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, launched Omjjara (momelotinib), a new treatment for myelofibrosis. This medication is approved by South Korea’s Ministry of Food and Drug Safety and is intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara operates as an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms like anemia, enlarged spleen, and fatigue. Its approval is supported by clinical trial data that demonstrated significant improvements in anemia, spleen size, and overall symptoms compared to existing treatments.

Who Are The Key Players Driving Competition In The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Read the full primary myelofibrosis market report here:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Regions Are Projected To Dominate The Primary Myelofibrosis Market In The Coming Years?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Myelofibrosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Primary Myelofibrosis Market At The End Of The 2026–2030 Forecast Period?

The primary myelofibrosis market size has seen significant expansion in recent years. It is anticipated to increase from $0.84 billion in 2025 to $0.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. The factors contributing to this growth in previous periods include a scarcity of treatment choices, challenges with timely and accurate diagnosis, insufficient public understanding of the condition, a dependence on traditional medical interventions, and a relatively small number of patients.

The primary myelofibrosis market size is anticipated to undergo substantial growth in the upcoming years. It is projected to reach $1.14 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.2%. This expansion during the forecast period is attributable to the development of novel targeted therapies, increasing clinical trial activities, advancements in genetic and molecular diagnostics, growing investment in hematology research, and the rising adoption of personalized medicine. Significant trends expected during this period include heightened awareness and early diagnosis of primary myelofibrosis, an expansion in targeted therapies and personalized treatment approaches, increased utilization of advanced diagnostic tools, growth in clinical trials and research activities, and a focus on patient support programs and disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Primary Myelofibrosis Market?

The expanding occurrence of myelofibrosis is projected to drive the growth of the primary myelofibrosis market moving forward. Myelofibrosis is defined as an uncommon form of bone marrow cancer that interferes with the body’s normal blood cell production, resulting in significant scarring within the bone marrow, which in turn causes severe anemia, weakness, fatigue, and an enlarged spleen. This increase in myelofibrosis prevalence is largely attributed to the global aging population, given that the condition predominantly impacts individuals over 60, with extended life expectancies leading to more diagnoses. The growing incidence of myelofibrosis contributes to better management of primary myelofibrosis through stimulating research, improving early detection, expanding treatment choices, and fostering enhanced clinical guidelines and specialized care. As an illustration, a report released in November 2024 by the National Institute for Health and Care Excellence, an independent executive non-departmental public body based in the UK, indicated that myelofibrosis affects 3.2 per 100,000 people in the UK, with an incidence rate of 0.6 per 100,000. Consequently, the rising prevalence of myelofibrosis is propelling the expansion of the primary myelofibrosis market.

What Segment Types Make Up The Primary Myelofibrosis Market?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Market Trends Are Creating New Opportunities In The Primary Myelofibrosis Market?

Leading companies within the primary myelofibrosis market are concentrating on developing innovative products, such as Janus kinase 2 inhibiting tablets, to enhance symptom control and slow disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral medications designed to block the activity of the JAK2 enzyme, which plays a role in the abnormal signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets contribute to reducing spleen size, alleviating symptoms of fatigue and bone pain, and impeding the disease’s advancement. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, launched Omjjara (momelotinib), a new treatment for myelofibrosis. This medication is approved by South Korea’s Ministry of Food and Drug Safety and is intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara operates as an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms like anemia, enlarged spleen, and fatigue. Its approval is supported by clinical trial data that demonstrated significant improvements in anemia, spleen size, and overall symptoms compared to existing treatments.

Who Are The Key Players Driving Competition In The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Read the full primary myelofibrosis market report here:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Regions Are Projected To Dominate The Primary Myelofibrosis Market In The Coming Years?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Myelofibrosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Primary Myelofibrosis Market At The End Of The 2026–2030 Forecast Period?

The primary myelofibrosis market size has seen significant expansion in recent years. It is anticipated to increase from $0.84 billion in 2025 to $0.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. The factors contributing to this growth in previous periods include a scarcity of treatment choices, challenges with timely and accurate diagnosis, insufficient public understanding of the condition, a dependence on traditional medical interventions, and a relatively small number of patients.

The primary myelofibrosis market size is anticipated to undergo substantial growth in the upcoming years. It is projected to reach $1.14 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.2%. This expansion during the forecast period is attributable to the development of novel targeted therapies, increasing clinical trial activities, advancements in genetic and molecular diagnostics, growing investment in hematology research, and the rising adoption of personalized medicine. Significant trends expected during this period include heightened awareness and early diagnosis of primary myelofibrosis, an expansion in targeted therapies and personalized treatment approaches, increased utilization of advanced diagnostic tools, growth in clinical trials and research activities, and a focus on patient support programs and disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Primary Myelofibrosis Market?

The expanding occurrence of myelofibrosis is projected to drive the growth of the primary myelofibrosis market moving forward. Myelofibrosis is defined as an uncommon form of bone marrow cancer that interferes with the body’s normal blood cell production, resulting in significant scarring within the bone marrow, which in turn causes severe anemia, weakness, fatigue, and an enlarged spleen. This increase in myelofibrosis prevalence is largely attributed to the global aging population, given that the condition predominantly impacts individuals over 60, with extended life expectancies leading to more diagnoses. The growing incidence of myelofibrosis contributes to better management of primary myelofibrosis through stimulating research, improving early detection, expanding treatment choices, and fostering enhanced clinical guidelines and specialized care. As an illustration, a report released in November 2024 by the National Institute for Health and Care Excellence, an independent executive non-departmental public body based in the UK, indicated that myelofibrosis affects 3.2 per 100,000 people in the UK, with an incidence rate of 0.6 per 100,000. Consequently, the rising prevalence of myelofibrosis is propelling the expansion of the primary myelofibrosis market.

What Segment Types Make Up The Primary Myelofibrosis Market?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Market Trends Are Creating New Opportunities In The Primary Myelofibrosis Market?

Leading companies within the primary myelofibrosis market are concentrating on developing innovative products, such as Janus kinase 2 inhibiting tablets, to enhance symptom control and slow disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral medications designed to block the activity of the JAK2 enzyme, which plays a role in the abnormal signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets contribute to reducing spleen size, alleviating symptoms of fatigue and bone pain, and impeding the disease’s advancement. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, launched Omjjara (momelotinib), a new treatment for myelofibrosis. This medication is approved by South Korea’s Ministry of Food and Drug Safety and is intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara operates as an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms like anemia, enlarged spleen, and fatigue. Its approval is supported by clinical trial data that demonstrated significant improvements in anemia, spleen size, and overall symptoms compared to existing treatments.

Who Are The Key Players Driving Competition In The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Read the full primary myelofibrosis market report here:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Regions Are Projected To Dominate The Primary Myelofibrosis Market In The Coming Years?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Myelofibrosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the primary myelofibrosis market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Primary Myelofibrosis Market reach by 2030 starting from 2026 levels?

The market size for primary myelofibrosis has demonstrated substantial growth in recent times. This market is anticipated to expand from $0.84 billion in 2025 to $0.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.4%. The increase observed in previous periods can be linked to factors such as limited available treatments, issues with delayed diagnosis and misdiagnosis, a low level of disease awareness, dependence on traditional therapies, and a small patient demographic.

The primary myelofibrosis market size is projected to undergo significant expansion over the next few years. It is expected to reach $1.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. The expansion during this forecast period can be ascribed to the development of novel targeted therapies, a rise in clinical trial activities, advancements in genetic and molecular diagnostics, increasing investment in hematology research, and the growing adoption of personalized medicine. Prominent trends expected in this timeframe include heightened awareness and early detection of primary myelofibrosis, the proliferation of targeted therapies and individualized treatment methods, a wider embrace of advanced diagnostic tools, an increase in clinical trials and research endeavors, and a focus on patient support programs and disease management strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

Which Drivers Are Influencing Long-Term Growth In The Primary Myelofibrosis Market?

The anticipated rise in myelofibrosis cases is projected to significantly advance the expansion of the primary myelofibrosis market in the future. Myelofibrosis is defined as a rare bone marrow malignancy that interferes with the normal generation of blood cells, causing substantial scar tissue formation within the bone marrow, which in turn leads to profound anemia, general weakness, exhaustion, and an enlarged spleen. This growing occurrence of myelofibrosis largely stems from an aging demographic, given that the disease predominantly affects individuals exceeding 60 years of age, and increased life expectancy contributes to a greater volume of diagnosed instances. An elevated prevalence of myelofibrosis enhances the management of primary myelofibrosis through stimulating research efforts, improving early detection, broadening available treatment choices, and fostering superior clinical protocols and specialized patient attention. As an illustration, a report released in November 2024 by the National Institute for Health and Care Excellence, an independent executive non-departmental public body based in the UK, indicated that myelofibrosis affects 3.2 per 100,000 people in the UK, with an incidence rate of 0.6 per 100,000. Consequently, the expanding occurrence of myelofibrosis is fueling the expansion of the primary myelofibrosis market.

How Is The Primary Myelofibrosis Market Divided Into Segments?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Trends Are Guiding The Evolution Of The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are concentrating on developing innovative products, specifically Janus kinase 2 inhibiting tablets, to enhance symptom management and impede disease progression. Janus kinase 2 (JAK2) inhibiting tablets function as oral medications that impede the JAK2 enzyme’s activity, which plays a role in the irregular signaling pathways leading to excessive blood cell production in primary myelofibrosis. These tablets are effective in decreasing spleen volume, easing symptoms of fatigue and bone pain, and decelerating the disease’s advancement. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology firm based in Korea, introduced Omjjara (momelotinib), a novel therapy for myelofibrosis. South Korea’s Ministry of Food and Drug Safety has approved it for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also suffer from moderate to severe anemia. Omjjara is an oral drug that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), thereby successfully treating symptoms including anemia, an enlarged spleen, and fatigue. Its approval is substantiated by clinical trial findings showing substantial improvements in anemia, spleen size, and overall symptoms when compared to currently available therapies.

Which Major Industry Participants Are Leading The Primary Myelofibrosis Market Growth?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Primary Myelofibrosis Market?

North America was the largest region in the primary myelofibrosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Primary Myelofibrosis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2026, By The Business Research Company

Myelodysplastic Syndrome Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Primary Myelofibrosis Market Expected To Become By 2029 Compared With Its 2025 Level?

The primary myelofibrosis market has experienced significant growth in recent years. It is anticipated to increase from $0.79 billion in 2024 to $0.84 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.4%. This historical expansion can be attributed to factors such as improved disease recognition among medical professionals, the increasing application of JAK inhibitors, enhanced diagnostic capabilities and genetic testing, greater availability of hematology specialists for patients, and a rise in clinical trial initiatives.

The primary myelofibrosis market is projected to experience substantial growth in the upcoming years. This market is anticipated to expand, reaching $1.07 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.2%. The expected growth during this forecast period stems from factors such as an expanding pipeline of innovative therapies, a rising demand for treatments that modify the disease, increasing prevalence within aging demographics, a growing emphasis on combination treatment strategies, and heightened investment from pharmaceutical and biotech enterprises. Significant trends for the forecast duration encompass progress in targeted drug development, the incorporation of next-generation sequencing (ngs) in diagnostic procedures, technology-enabled monitoring solutions, advancements in combination therapy protocols, and improvements in bone marrow fibrosis imaging techniques.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Are The Key Drivers Of Growth In The Primary Myelofibrosis Market?

The projected increase in the occurrence of myelofibrosis is anticipated to drive the expansion of the primary myelofibrosis market moving forward. Myelofibrosis is a rare form of bone marrow cancer that interferes with the body’s normal generation of blood cells, resulting in extensive scarring within the bone marrow, which then causes severe anemia, weakness, fatigue, and an enlarged spleen. The heightened prevalence of myelofibrosis is primarily attributed to the world’s aging population, given that the condition typically impacts individuals over the age of 60, and extended life expectancies are leading to a greater number of diagnosed cases. This rising prevalence of myelofibrosis enhances the management of primary myelofibrosis by fostering research, improving early detection, expanding therapeutic options, and advocating for better clinical guidelines and specialized medical attention. For instance, in November 2024, a report published by the National Institute for Health and Care Excellence, an independent executive non-departmental public body based in the UK, stated that myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. Therefore, the growing prevalence of myelofibrosis is a significant factor boosting the primary myelofibrosis market.

What Are The Emerging Segments Gaining Attention In The Primary Myelofibrosis Market?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

What Trends Are Expected To Drive The Primary Myelofibrosis Market?

Leading companies in the primary myelofibrosis market are concentrating on developing innovative solutions, such as Janus kinase 2 inhibiting tablets, to enhance symptom control and slow the advancement of the disease. Janus kinase 2 (JAK2) inhibiting tablets are oral drugs that obstruct the action of the JAK2 enzyme, which plays a role in the irregular signaling pathways causing excessive blood cell production in primary myelofibrosis. These tablets contribute to reducing spleen size, alleviating symptoms of fatigue and bone pain, and decelerating disease progression. For example, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, introduced Omjjara (momelotinib) as a novel treatment for myelofibrosis. It has been approved by South Korea’s Ministry of Food and Drug Safety and is designated for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also suffer from moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), thereby effectively addressing symptoms like anemia, an enlarged spleen, and fatigue. Its approval is substantiated by clinical trial data that demonstrated notable improvements in anemia, spleen size, and overall symptoms compared to existing treatments.

Which Leading Players Are Enhancing Their Primary Myelofibrosis Market Presence Worldwide?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Primary Myelofibrosis Market?

North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Primary Myelofibrosis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

Browse Through More Reports Similar to the Global Primary Myelofibrosis Market 2025, By The Business Research Company

Myelodysplastic Syndrome Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Myeloproliferative Disorders Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Thrombectomy Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/thrombectomy-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Primary Myelofibrosis Market From 2025 to 2029?

The market size for primary myelofibrosis has experienced significant growth in the past few years. Estimates predict the market size will increase from $0.79 billion in 2024 to $0.84 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.4%. This growth during the historical period is ascribed to factors such as enhanced disease recognition among healthcare professionals, an increasing utilization of jak inhibitors, improved diagnostic techniques and genetic testing capacities, heightened patient access to hematological experts, and an upswing in clinical trial activities.

The market for primary myelofibrosis is set to experience robust growth in the ensuing years, propelling to a value of $1.07 billion by 2029 with a compound annual growth rate (CAGR) of 6.2%. Factors leading to this expansion throughout the forecast period include the burgeoning pipeline of innovative therapies, the heightened need for treatments that alter disease progression, increasing occurrence among the elderly, a growing focus on combination therapies, and more investment from pharmaceutical and biotech companies. Key trends predicting these market changes encompass the rise in target-specific drug advancements, the use of next-generation sequencing (ngs) in diagnostic practices, the emergence of technology-based monitoring options, the evolution of combination therapy procedures, and improvements in imaging techniques for bone marrow fibrosis.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp

What Elements Are Contributing To Growth In The Primary Myelofibrosis Market?

The anticipated rise in myelofibrosis cases is set to trigger expansion in the primary myelofibrosis market. Myelofibrosis, a unique bone marrow cancer type, interrupts the typical blood cell production process in the body, causes extensive bone marrow scarring, and leads to severe anemia, weakness, fatigue, and spleen enlargement. A primary factor in the growing prevalence of myelofibrosis is the aging demographic, given that individuals over 60 are most likely to develop the disease, and increased life expectancy has led to a surge in diagnosed cases. This increase in myelofibrosis cases drives improvements in managing primary myelofibrosis by encouraging research, supporting early detection, expanding treatment choices, and fostering enhanced clinical guidelines and specialist care. For example, a November 2024 report from the UK’s independent executive non-departmental public body, the National Institute for Health and Care Excellence, revealed a myelofibrosis prevalence rate of 3.2 per 100,000 individuals in the UK and an incidence rate of 0.6 per 100,000. Consequently, the escalating prevalence of myelofibrosis fuels the expansion of the primary myelofibrosis market.

Which Segments Are Detailed In The Global Primary Myelofibrosis Market Report?

The primary myelofibrosis market covered in this report is segmented –

1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types

2) By Services: Treatment, Diagnosis

3) By Dosage Forms: Solid, Liquids, Other Dosage Forms

4) By Age: Adult, Child, Geriatric

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations

2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis

3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders

4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis

Which Emerging Trends And Strategic Shifts Are Shaping The Primary Myelofibrosis Market?

Key players in the primary myelofibrosis market are centering their efforts on creating groundbreaking products like Janus kinase 2 inhibiting tablets in order to enhance symptom management and slow the progression of the disease. These oral medications, which hinder the activity of the JAK2 enzyme, play a significant role in halting the aberrant signaling pathways that lead to an excess production of blood cells in primary myelofibrosis. This helps in minimizing the size of the spleen, relieving fatigue and bone pain, and decelerating disease progression. For instance, in March 2025, a significant development was witnessed when GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotech firm based in Korea, rolled out Omjjara (momelotinib), a fresh treatment option for myelofibrosis. Approved by South Korea’s Ministry of Food and Drug Safety, the treatment is designed for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who are also suffering from moderate to severe anemia. Omjjara is a JAK1 and JAK2 inhibitor and also inhibits activin A receptor type 1 (ACVR1), efficiently treating symptoms like anemia, increased spleen size, and fatigue. The endorsement of the treatment is backed by clinical trial data that indicates significant improvements in symptoms compared to traditional treatments.

Who Are The Key Contributors To Growth In The Primary Myelofibrosis Market?

Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report

Which Region Is Projected To Lead The Primary Myelofibrosis Market By 2025?

North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24669&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model